Kaitlyn Wong, MD
Internal Medicine · Brooklyn, NYNPI 1801107818
Payments from drug & device makers
Across 373 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- GSK$636
- Gilead$586
- Lilly USA, LLC$579
- Esperion Therapeutics, Inc.$516
- plus $3K from 25 others
What the payments were for
- Consulting fees$140%
- Food & beverage$8,38698%
- Education$1712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 76 | $1,646 |
| Boehringer Ingelheim | 68 | $1,409 |
| GSK | 30 | $636 |
| Gilead | 29 | $586 |
| Lilly USA, LLC | 33 | $579 |
| Esperion Therapeutics, Inc. | 7 | $516 |
| Amarin Pharma, Inc. | 29 | $423 |
| Amgen(2 entities) | 10 | $413 |
| Exact Sciences | 11 | $406 |
| Merck | 20 | $336 |
| Novo Nordisk | 20 | $331 |
| Phathom Pharmaceuticals, Inc. | 4 | $300 |
| Abbott | 4 | $286 |
| Hologic Sales And Service, LLC | 1 | $125 |
| Insmed, Inc. | 4 | $95 |
| AbbVie(2 entities) | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| IBSA Pharma Inc. | 3 | $42 |
| Eisai Inc. | 1 | $28 |
| Viatris Specialty LLC | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Radius Health, Inc. | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $23 |
| Lupin Inc. | 2 | $22 |
| Pfizer | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$450
- NEXLETOL$450
- FARXIGA$250
- VOQUEZNA$250
- Prolia$125
- Sexually Transmitted Infectious Disease$125
- Vemlidy$125
- EVENITY$125
- Cologuard Collection Kit$114
- Omnilink Elite vascular stent system$112
How this compares
$8,571 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 904 | $445,313 |
| FarxigaDapagliflozin Propanediol | 335 | $383,741 |
| Diclofenac Epolamine | 471 | $323,896 |
| JardianceEmpagliflozin | 150 | $186,527 |
| JanuviaSitagliptin Phosphate | 112 | $146,611 |
| ProliaDenosumab | 70 | $119,436 |
| GlyxambiEmpagliflozin/Linagliptin | 94 | $103,002 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 151 | $99,565 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $99,468 |
| RybelsusSemaglutide | 48 | $90,921 |
| VemlidyTenofovir Alafenamide | 63 | $89,737 |
| TradjentaLinagliptin | 66 | $55,314 |
| JanumetSitagliptin Phos/Metformin Hcl | 49 | $50,000 |
| TrulicityDulaglutide | 34 | $40,692 |
| EliquisApixaban | 43 | $39,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,646 | $483,306486 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy | $1,409 | $365,145328 claims |
| MerckJanuvia, Janumet | $336 | $196,611161 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta | $636 | $136,617327 claims |
| AmgenProlia | $413 | $119,43670 claims |
| Novo NordiskRybelsus, Ozempic | $331 | $108,00665 claims |
| GileadVemlidy | $586 | $89,73763 claims |
| PfizerEliquis, Abrysvo | $20 | $50,51680 claims |
| Lilly USA, LLCTrulicity | $579 | $40,69234 claims |
| AbbVieLinzess, Synthroid | $75 | $34,696193 claims |
| Johnson & JohnsonXarelto | $14 | $16,75122 claims |
| Esperion Therapeutics, Inc.Nexlizet | $516 | $9,37518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.